The Indian Patent Office took heat for its incompetence when Valganciclovir was granted patent in 2007. The matter was remanded back to the Patent Office by the IPAB to reconsider and this time the patent was revoked. This decision comes at the time when India’s National intellectual property policy is in its final stages, awaiting approval by the Cabinet and with mounting International pressure from Pharmaceutical lobbies, rejecting patent of Pharmaceutical giant F.Hoffmann-La Roche AG will have repercussions. But why…